Resources from the same session
1083MO - Brain metastases and survival evaluation in the SECOMBIT trial
Presenter: Paolo Ascierto
Session: Mini oral session - Melanoma and other skin tumours
Resources:
Abstract
Slides
Webcast
1084MO - Nivolumab plus ipilimumab in melanoma patients with asymptomatic brain metastases: 7-year outcomes and quality of life from the multicenter phase III NIBIT-M2 trial
Presenter: Anna Di Giacomo
Session: Mini oral session - Melanoma and other skin tumours
Resources:
Abstract
Slides
Webcast
Invited Discussant 1083MO and 1084MO
Presenter: Georgina Long
Session: Mini oral session - Melanoma and other skin tumours
Resources:
Slides
Webcast
LBA50 - Three-year survival with tebentafusp in previously untreated metastatic uveal melanoma in a phase III trial
Presenter: Sophie Piperno-Neumann
Session: Mini oral session - Melanoma and other skin tumours
Resources:
Abstract
Slides
Webcast
1086MO - Lifileucel tumor-infiltrating lymphocyte (TIL) cell therapy in patients (pts) with advanced mucosal melanoma after progression on immune checkpoint inhibitors (ICI): Results from the phase II C-144-01 study
Presenter: Evidio Domingo-Musibay
Session: Mini oral session - Melanoma and other skin tumours
Resources:
Abstract
Slides
Webcast
LBA51 - Unraveling relatlimab (RELA)-specific biology using biomarker analyses in patients with advanced melanoma treated with nivolumab (NIVO)+RELA or NIVO alone in RELATIVITY-047
Presenter: Evan Lipson
Session: Mini oral session - Melanoma and other skin tumours
Resources:
Abstract
Slides
Webcast
1087MO - A single arm phase II, multicenter trial to evaluate the clinical activity and safety of avelumab plus cetuximab in unresectable stage III or IV cutaneous squamous cell carcinoma: First results from the AliCe study
Presenter: Juergen Becker
Session: Mini oral session - Melanoma and other skin tumours
Resources:
Abstract
Slides
Webcast
1088MO - A phase II study of neoadjuvant cemiplimab for stage II to IV cutaneous squamous cell carcinoma (CSCC): One-year follow-up
Presenter: Neil Gross
Session: Mini oral session - Melanoma and other skin tumours
Resources:
Abstract
Slides
Webcast
LBA52 - A randomized phase Ib/II study of the selective small molecule AXL inhibitor bemcentinib in combination with either dabrafenib/trametinib or pembrolizumab in patients with metastatic melanoma
Presenter: Oddbjørn Straume
Session: Mini oral session - Melanoma and other skin tumours
Resources:
Abstract
Slides
Webcast
Invited Discussant 1087MO, 1088MO and LBA52
Presenter: Caroline Robert
Session: Mini oral session - Melanoma and other skin tumours
Resources:
Slides
Webcast